Phase II study of ATRAGEN (liposomal tretinoin) [AR 623] in patients with relapsed or refractory Hodgkin's disease
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2012
At a glance
- Drugs AR 623 (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 27 Jul 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 04 Oct 2005 New trial record.